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Background: As exome sequencing expands as a diagnostic tool, patients and providers 
have voiced concerns about the breadth and scope of potential results. Particularly, 
genetic counselors perceive challenges to prioritizing complex information during 
informed consent sessions. 
Objectives: This study first sought to characterize challenges to the informed consent 
process for exome sequencing.  Secondly, it aimed to understand how genetic counselors 
prioritize elements of obtaining consent for clinical exome sequencing, and thirdly, 
whether counselor factors influence prioritization.  
Methods: Aim one was addressed through a systematic review of the published literature 
from January 2010 to February 2017.  Seventeen identified challenges culled from the 
review informed the development of a best worst scale (BWS) used to address aim two. 
Eleven attributes for the BWS task were finalized with input from two focus groups and 
were assembled into choice sets using a balanced incomplete block design.  A survey 
presenting the BWS tasks and assessing perceptions of communication and target 
efficacy and tolerance for ambiguity alongside demographics was assembled to address 
aim three. The survey was distributed to members of the National Society of Genetic 
Counselors via their email listserv. BWS data was analyzed using a counts based method, 
and stratified analyses were run with two-tailed t tests controlling for reported counselor 
factors. 
Results: 342 genetic counselors completed the survey. Counselors with more experience 
ordering exome sequencing were significantly more likely to work in pediatrics and 
reported higher communication and target efficacy. Ranking of best-worst scores 
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revealed that genetic counselors prioritize collaborative decision-making, assessing 
patient understanding and managing expectations, with the least emphasis placed on 
discussing technological complexities. Stratified analyses found that counselors with 
more exome experience, and those who reported higher target efficacy, were significantly 
more likely to prioritize discussion of variants of uncertain significance (p<0.05).  
Discussion: Genetic counselors perceive challenges in addressing the many complicated 
aspects of exome sequencing, particularly secondary findings and limitations of testing.  
Counselors report intentions to prioritize aspects of informed consent that focus on 
addressing individual patient needs.  Additionally, participant characteristics influence 
discussion of potential uncertain results. Further research should explore how these 
priorities are exhibited in practice. 
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PART ONE: INTRODUCTION 
 
Objectives and Specific Aims 
Genomic sequencing is becoming increasingly incorporated into clinical and 
research practice as a molecular diagnostic tool.  While there is much excitement 
surrounding the potential for this new technology, concerns about the breadth and 
uncertainty inherent to the testing methodology have been voiced by clinicians, 
researchers and patients (Bertier et al., 2016; Levenseller et al., 2014). The wide scope of 
possible results and evolving methods for data interpretation of information pose 
particular challenges to the informed consent process that must include discussion of the 
potential for secondary findings, variants of uncertain significance, and uninformative 
negative results (Bernhardt et al, 2015). Multiple stakeholders have reached a general 
consensus about the necessary content required for informed consent to exome 
sequencing, but variability persists in understanding how this information is prioritized 
and communicated (Ayuso et al., 2013; ACMG Board of Directors, 2013). Genetic 
Counselors are often responsible for obtaining consent in both clinical and research 
settings, and have valuable insight to offer into how they approach consent for exome 
sequencing (Machini et al., 2014). 
 
Objective: This study seeks to understand challenges to the informed consent process for 
exome sequencing as perceived by healthcare providers, researchers and patients, as well 
as to explore how genetic counselors prioritize information and counseling elements 
when obtaining consent.     
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Aim 1: To characterize reported challenges to obtaining informed consent for 
exome sequencing through a systematic review of the published literature.  
Aim 2: To understand how genetic counselors prioritize essential elements of 
informed consent for exome sequencing when approaching consent sessions in a 
pediatric clinical setting. 
Aim 3: To explore whether prioritization of elements of informed consent is 
mediated by genetic counselor factors such as experience with exome sequencing, 
tolerance for ambiguity and perceived communication and target efficacies.  
 
The results of this study will be presented in the form of two manuscripts. The 
first, entitled Challenges to informed consent for genomic sequencing: a systematic 
literature review, addresses Aim one.  The second manuscript, Challenges to informed 
consent for exome sequencing: a best worst scaling experiment, describes the findings of 
a survey study designed to address Aims two and three. 
 
Background and Literature Review 
The Shift Towards Exome Sequencing & Challenges to Informed Consent 
Exome sequencing has emerged as a novel tool for identifying disease causing 
and risk modifying variants throughout the genome, and has increasingly been offered as 
a step in the pediatric diagnostic process. Reports of the clinical utility of exome 
sequencing have demonstrated a 25-31% success rate in identifying pathogenic variants 
in patients referred for testing through a clinical laboratory due to a suspected genetic 
condition (Yang et al., 2014; Farwell et al., 2014).  However, many questions have been 
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raised as to how this new technology will effectively become integrated into clinical 
practice, including the scope of information it can provide, how results will be interpreted 
and communicated to patients, and whether the infrastructure exists to support the 
transition (Biesecker et al., 2012; Bertier et al., 2016).  This large-scale testing strategy 
represents a paradigm shift from traditional genetic testing that has targeted specific 
genes based on phenotypic data and familial risk assessment, as mutations may now be 
identified independently of the clinical indication (Hooker et al., 2014).  The possibility 
for secondary or incidental findings and the greater yield of variants of uncertain 
significance makes anticipation of an individual’s results increasingly difficult.   
These changes present considerable challenges to the informed consent process, 
which has previously involved discussion of the specific conditions under consideration.  
As results from exome sequencing cannot be predicted in advance, genetic counselors 
have discussed the need to expand and adapt the informed consent process to incorporate 
discussion of the inherent uncertainty and the potential for findings that cannot be 
interpreted clearly with current data (Bernhardt et al., 2015). In order to organize the 
wide breadth of information, researchers and clinicians have aimed to identify a minimal 
list of information that must be included in the informed consent process for exome 
sequencing. Recommendations put forth by the ACMG Board of Directors broadly 
advocate for discussion of expected outcomes of testing including the type and likelihood 
of results that will or will not be returned, as well as the risks, benefits, limitations, 
alternatives to testing and potential implications for relatives (ACMG Board of Directors, 
2013). A systematic review of fourteen papers published by professional societies or 
experts in the field identified seven domains necessary to obtaining informed consent that 
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were consistently referenced in the included studies. Broadly, these elements of the 
informed consent process were defined as: pre-test counseling, scope, description, 
benefits, risks, storage and future uses of test results, and management of incidental 
findings (Ayuso et al., 2013). 
While there appears to be consensus among researchers and clinicians about the 
necessary inclusion of these general elements, there is considerable heterogeneity in the 
specific content and level of detail provided under each domain.  Content analysis of 
consent documents utilized in nine genomic research studies revealed evidence for 
significant variability in the descriptions of risks and benefits and in the categorization of 
potential result types (Henderson et al., 2014). Furthermore, genetic counselors and 
research coordinators report varying their approach based on the setting, indication for 
testing, and age and health status of the patient (Bernhardt et al., 2015).    
In addition to the wide-ranging decisions about content and detail, the way that 
information is presented and prioritized is also highly variable in terms of length of time 
and style of communication (Arora et al., 2016). Since it is impossible to predict the type 
of result that an individual can expect to receive, it becomes difficult to prioritize the 
elements of the informed consent process that will ultimately be most relevant to any 
given patient. Thus counselors must make decisions about which information to prioritize 
and how to present the content when time with patients is limited. A variety of techniques 
have been suggested including “binning” information about potential results into broader 
categories based on clinical relevance and presenting the information in a tiered fashion, 
though more research is needed to evaluate the outcomes of using these methods 
(Bradbury et al, 2015). A greater understanding of the factors influencing decisions about 
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which information to prioritize and how to communicate the scope of exome sequencing 
is needed to further develop these techniques and guide the evolution of the informed 
consent process (Khan et al, 2015).  
The Communication Process and Informed Consent 
In addition to characterizing the content of informed consent, previous research 
has also explored the communication process within genetic counseling sessions.  Studies 
of the process of genetic counseling can help to continually refine goals and practice 
definitions, an area that may continue to develop as genetic counselors adapt to a 
changing field (Biesecker & Peters, 2001). Genetic counseling has been defined as “the 
process of helping people understand and adapt to the medical, psychological and 
familial implications of genetic contributions to disease” and incorporates interpretation, 
education and counseling (Resta et al., 2006). Along these lines, studies of the 
communication process within genetic counseling sessions have suggested that 
information sharing strategies that are lower in counselor verbal dominance and higher in 
active exchange facilitate improved client understanding and satisfaction (Roter et al., 
2006).   
Despite characterization of genetic counseling as a psychoeducational process, 
communication studies have identified educational information as the primary focus in 
the majority of genetic counseling sessions. In a recent systematic review of 22 published 
studies, the authors reported that counselor speech, often focused on biomedical and 
education content, dominated the session in several studies (Paul et al., 2015). This 
pattern has also been observed in disclosure sessions for exome sequencing. Despite clear 
attempts to assess patient understanding, providers most often followed patients’ reported 
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confusion with more complex biomedical information with minimal opportunities for 
interactivity (Walser et al., 2017). 
These findings suggest an apparent disconnect between genetic counselors’ stated 
psychotherapeutic goals, and communication patterns that arise within the counseling 
session that focus primarily on addressing educational goals. The greater informational 
demand associated with informed consent for exome sequencing has the potential to 
exacerbate this discrepancy. Pediatric consent sessions are particularly challenging, as the 
decision to receive secondary findings could have potential consequences for the child’s 
developing identity as well as other family members (Werner-Lin et al., 2016). The 
importance of obtaining meaningful assent from children can also pose a challenge and 
complicate family decision-making. A study of 44 pediatric consent sessions in a clinical 
setting found that the majority of healthcare providers attempted to engage pediatric 
patients and that this was associated with a significant increase in child verbal 
participation (Miller et al., 2017). Though parents are ultimately empowered to make 
testing decisions, child involvement is ethically important and may increase patients’ 
ability to make informed decisions about future analysis of their sample after turning 
eighteen (Werner-Lin et al., 2016).  
As next generation sequencing enters clinical care, genetic counselors have an 
opportunity to play a critical role in addressing patient psychosocial and informational 
needs, though this transition will require increased attention to communication and 
counseling strategies used to convey the wide scope of possible testing outcomes (Austin 
et al., 2014). Despite experience with more traditional models of informed consent, 
genetic counselors have voiced some trepidation about their abilities to effectively 
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communicate increasingly complex and uncertain information when obtaining informed 
consent for exome sequencing (Machini et al., 2014). Multiple counselors involved in the 
informed consent process have reported feeling overwhelmed by the scope of exome 
sequencing when it was first introduced, but expressed a shift in their counseling style 
from information dominated to more patient-centered as they gained experience and 
comfort with the content (Bernhardt et al., 2015; Wynn, 2016). A methodological shift 
from following the order of the consent form to summarizing main points and allowing 
patient questions to guide in-depth discussion has been described repeatedly. These 
observations suggest that doubts about one’s ability to communicate effectively may 
influence information management decisions about the amount of information, content 
prioritization, and the degree of direct information sharing (Afifi & Weiner, 2004). A 
more thorough understanding of factors that contribute to the prioritization of different 
aspects of informed consent may help to identify barriers to patient-centered 
communication throughout the informed consent process.  
 
Parent Informational Needs Surrounding Diagnostic Genomic Testing 
 Perceptions of parents’ ability to understand and manage complex information 
central to the informed consent process may also play a contributory role in developing 
an approach to information sharing. Effective communication could be compromised if 
inaccurate assumptions are made about parents’ abilities to process complicated 
information related to their child’s diagnosis, both cognitively and emotionally. In 
contrast to some of the misgivings voiced by genetic counselors and the scientific 
community, patients and parents have been largely enthusiastic about the wealth of 
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information available through exome sequencing, and have expressed perceptions of their 
ability to adjust to multiple types of results (Sapp et al., 2014; Krabbenborg et al., 2016).   
Similar concerns about patients’ ability to cope with large-scale genomic data 
were raised in conjunction with the introduction of microarray technology.  Multiple 
studies have addressed parental informational needs surrounding microarray testing as a 
pediatric diagnostic tool, and may provide insight into factors that affect parental 
responses to exome sequencing. Responses to microarray testing are nuanced and 
variable depending on the particular situation, though reported reactions suggest that the 
majority of parents perceived utility of microarray results even when a definitive genetic 
cause was not identified and medical management was not changed (Reiff et al., 2015).  
Parents have also demonstrated flexibility and resilience in accommodating new 
information (Wilkins et al., 2016). In qualitative studies, parents articulated dimensions 
of perceived utility including relief and fulfillment of parental responsibilities even when 
results were uncertain, with some parents accepting uncertainty as an inherent component 
of new technology (Reiff et al., 2012; Hayeems et al., 2016).   
Early studies of parental attitudes towards whole exome sequencing have 
generally drawn the same conclusions, as parents report overall satisfaction with the test, 
despite varying degrees of frustration surrounding uncertainty and difficulty rearranging 
previous beliefs about the cause of their child’s illness (Krabbenborg et al., 2016).  
Parents have also expressed a desire to know as much information as possible, including 
variants of uncertain significance and secondary findings, and may actually request 
information that providers are more reluctant to share (Middleton et al., 2016).  
Furthermore, parents who were interviewed as part of a qualitative study of 25 parents of 
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children with rare diseases shared that they have drawn upon their ability to cope with 
previous health problems as evidence that they can adapt to new health threats (Sapp et 
al., 2014). While these findings do not deny the emotional and informational weight of 
exome sequencing results and the importance of approaching these conversations 
thoughtfully, they provide evidence of parental capacities to cope with complex and 
uncertain situations.   
In light of parental desire for diagnostic information, studies have aimed to 
identify areas where patient and provider informational priorities have differed when 
conceptualizing genetic testing options. A survey of 199 genetic counselors and 152 
women who had undergone fetal microarray testing, found that genetic counselors and 
patients prioritized information differently, with counselors placing greater emphasis on 
information about testing logistics and potential limitations. In this study, surveyed 
patients prioritized the importance of information about the severity and prevalence of 
diseases that could be detected, and guidance about decisions that other couples have 
made in similar situations (Walser et al., 2015). Patients often report a desire for 
information about all possible outcomes, and in an effort to satisfy this need counselors 
may demonstrate a tendency to provide an excess of information about their clinical 
rationale and population level statistics. This strategy was illuminated in a study of 101 
prenatal genetic counseling sessions, in which clinicians emphasized the ability of the test 
to detect pathophysiology and numerical risk figures, while patients were primarily 
focused on creating an individualized picture of the meaning of the result and managing 
vulnerability attached to being labeled as “at risk” (Hunt et al., 2005).  Furthermore, these 
authors concluded that patient understanding and information recall was not 
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comparatively better after counseling sessions that were more dense in information 
provision. 
These questions have also been explored in the context of pediatric exome 
sequencing.  A recent study assessed informational needs of parents throughout the 
testing process for their children from consent to results disclosure. Patients reported 
feeling that discussion included too much information and medical jargon, and did not 
address the potential impact of results on their daily life and care plans for their child 
(Krabbenborg et al., 2016).  Additionally, parents reported reluctance to broach their 
concerns about these issues, suggesting that they could have benefitted from a more 
tailored and interactive protocol. These findings were echoed in a study of exome result 
disclosures, in which patients were most engaged during discussions about how the 
results would or would not change medical management (Walser et al., 2017). Decisions 
surrounding the approach to information prioritization and communication during 
informed consent for exome sequencing may be influenced by counselors’ perception of 
their ability to manage uncertainty and communicate effectively, as well as perceptions of 
clients’ ability to understand and accept results.  Exploration of these relationships may 
help to clarify areas in which patient and provider communication strategies can become 
better aligned. 
 
Conceptual Framework and the Theory of Motivated Information Management 
 The proposed conceptual framework for this study (Figure 1) draws inspiration 
from the information provider perspective of the Theory of Motivated Information 
Management. The Theory of Motivated Information Management describes an interactive 
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process undertaken by information seekers and providers in which expected outcomes of 
communication and perceived efficacy are evaluated to develop an information sharing 
strategy (Afifi & Weiner, 2004). For the purpose of this study the provider perspective 
will be considered, specifically in relation to the role of perceived efficacy in mediating 
decision making about which and how much information to share. Perceived self-efficacy 
is a widely referenced concept in psychology, and has been defined as a person’s belief in 
their ability to succeed in ways that allow them to have influence over events that affect 
their life (Bandura, 1997). This study will focus on two components of efficacy described 
in the Theory of Motivated Information Management, communication efficacy and target 
efficacy, as they have been shown to have significant independent effects on information 
management decisions in previous studies (Fowler & Afifi, 2011).   
 
 
Figure 1.1: Framework Adapted from the Theory of Motivated Information Management 
 
Communication efficacy refers to an individual’s judgment of his or her ability to 
convey requested information effectively. Higher levels of communication efficacy have 
been shown to be significant predictors of the decision to seek health history information 
from family members in multiple studies of familial communication (Hovick, 2014; 
Fowler & Afifi, 2011). Intervention studies suggest that measures of communication self-
efficacy can be manipulated. A study of self-efficacy among 181 physicians who 
underwent a patient-centered communication training program, found that scores of self-
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efficacy in communication with patients and colleagues significantly increased following 
the intervention and that this gain in self-efficacy was stable when reassessed at six 
months (Norgaard et al., 2012). The observed roles of communication efficacy in 
influencing communication suggest that interventions like the training program aimed to 
increase communication efficacy in both clients and counselors may facilitate more 
complete information sharing (Hovick, 2014).  
Target efficacy refers to the provider’s perception of the information seeker’s 
ability and willingness to manage the information once it has been shared (Afifi & 
Weiner, 2004). Previous studies utilizing the Theory of Motivated Information 
Management have hypothesized that higher perceptions of target efficacy among 
information providers facilitate more direct styles of information sharing. One such study 
of partner discussions surrounding sexual health found that perceived target efficacy 
mediated the relationship between negative emotions and decisions to seek information, 
supporting a strong role for efficacy assessments in this model (Dillow & Labelle, 2014).  
The current study will aim to further this type of research by exploring whether efficacy 
assessments affect decisions about the nature of information sharing when consenting 
patients to exome sequencing. 
Genetic counselor factors included in the model were selected to explore whether 
there are systematic differences in information prioritization among counselors with 
differing baseline characteristics and lived experiences with exome sequencing. Ongoing 
experience with exome sequencing has been shown to influence the way that counselors 
approach the informed consent process over time (Bernhardt et al, 2015). Exposure to 
genomic sequencing has also been predictive of knowledge and understanding of the 
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risks and benefits of testing, though time in practice or setting were not significantly 
associated with these outcomes (Boland et al, 2015). This finding suggests that other 
factors aside from years of practice and employment in an academic setting may be more 
strongly related to comfort approaching genomic sequencing. For example, genetic 
counselors working in the field of pediatrics are significantly more likely to have ordered 
clinical exome sequencing than those in other specialties like prenatal and cancer genetics 
(Machini et al, 2014). In order to further characterize which factors contribute most 
significantly to information provision decisions the current study will include years in 
practice, setting, specialty, and number of times ordering whole exome sequencing.   
Previous research has also aimed to examine whether baseline personality 
characteristics influence the process and outcomes of genetic counseling. One such 
characteristic, tolerance for ambiguity, refers to an individual’s level of comfort with 
ambiguous situations. While previous studies relating tolerance for uncertainty to genetic 
testing uptake have shown that low tolerance for uncertainty may act as a motivator to 
pursue testing, this association may differ for exome sequencing due to the inherent 
uncertainty associated with the technology. In exploring this relationship, a study of 
research participants’ intentions to receive genomic sequencing results found that those 
with a lower baseline tolerance for uncertainty were less likely to seek medically non-
actionable results (Tabor et al., 2015). The current study will explore whether tolerance 
for ambiguity influences information sharing strategies when considered from the 
counselor perspective. As illustrated in the conceptual framework, these factors may 
interact to influence efficacy assessments which in turn mediate decisions about 
information management.   
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Methods: Best Worst Scaling 
 In order to determine how efficacy interacts with counselor information 
management decisions, it is important to accurately characterize the ways that counselors 
prioritize information when presented with complex genetic testing and limited time with 
patients.  Researchers have asked counselors to describe what information they consider 
most salient, though stated preferences may not match clinical reality.  A study that 
compared counselor-reported information priorities to transcripts from 101 prenatal 
counseling sessions found that counselors rarely include all of the information that they 
plan to share (Hunt et al., 2005).  This finding illuminates the need for alternative 
methods to direct questioning when attempting to elicit counselor information 
management decisions. 
  While traditionally designed for use in product development and market research, 
best worst scaling (BWS) has been widely applied in healthcare settings, primarily in 
studies to determine patient’s priorities in decision-making surrounding risks and benefits 
of experimental treatments (Cheung et al., 2016; Peay et al., 2014). Best worst scaling 
experiments aim to elicit values that are not observable to researchers by asking 
participants to weigh the relative importance of factors by repeatedly selection the ‘best’ 
and ‘worst’ attributes from a series of choice sets (Louivere et al., 2013). Recently, they 
have been used as part of a shift to more patient-centered assessments of healthcare that 
focus on the whole experience rather than medical outcomes alone (Ryan et al, 2008).  
BWS studies provide more information than traditional ranking methods by collecting 
data about the least favored attributes and eliminating the need for participants to 
discriminate among attributes ranked in the middle (Erdem & Rigby, 2013).    
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Random Utility Theory guides the underlying premise of best worst scaling 
experiments. This theory asserts that people make decisions about their preferences based 
upon a latent construct labeled “utility”, though they cannot access this construct 
consciously (Thurstone, 1927; McFadden, 1974). Decisions relating to this construct 
have systematic and random components, so identified patterns in selections among 
choice sets containing different combinations of attributes can be used to predict how the 
probability of a given choice changes when different options are presented (Louviere et 
al, 2013). This model characterizes the factors influencing random variability in decision-
making that can help to identify which attributes truly hold the most value.  In this study, 
BWS will be used to measure how genetic counselors prioritize elements of the informed 
consent process for pediatric clinical exome sequencing. 
Another conjoint analysis method, Discrete Choice modeling, was also considered 
during the development of this study. Discrete choice experiments involve selecting 
salient attributes of a product or treatment, each with multiple levels of importance, and 
then creating random combinations to create distinct profiles that the participant must 
choose between (Coast et al, 2011). The process of selecting one set of random 
combinations of attributes over another set forces the participant to activate decision-
making heuristics that they may not be able to explain directly. Despite methodological 
differences, BWS and Discrete Choice are both derived from the same underlying theory 
and have been shown to generate the same relative preference weights in an empirical 
comparison (Potoglou et al., 2011). While this suggests the validity of both methods, the 
cognitive processing involved in each may differ making a certain method more suitable 
to particular research questions.  In a study comparing the two methods, participants were 
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asked to talk aloud throughout their decision-making process.  These authors found that 
there was stronger evidence for the use of “trading”, or comparing two alternatives, 
during the Discrete Choice Experiment, though participants felt that the BWS exercise 
was less cognitively and ethically burdensome (Whitty et al, 2014).  BWS was selected 
for this study because Aims 2 and 3 would be best addressed by generated a ranking of 
prioritized counseling elements. Additionally, the attributes of interest were not 
conducive to division into levels and all elements are independently essential to obtaining 
informed consent.  
 Best worst scaling has been applied to evaluate preferences for healthcare 
provision using input from healthcare providers, patients and the general population 
(Cheung et al., 2016).  In the context of genomics, BWS has been used to assess 
physicians’ perceived barriers to implementing personalized medicine (Najafzadeh et al., 
2012).  In this study, 197 physicians, mostly primary care doctors, participated in a BWS 
experiment ranking the importance of factors influencing the decision to incorporate new 
genomic technology into their clinical practice. They found that participants most 
strongly considered the degree to which genetic testing is available and accessible.  
Appropriate training and clear professional guidelines were also highly valued 
(Najafzadeh et al., 2012). Another BWS study explored genetics professionals’ opinions 
for prioritizing and allocating resources to genetic testing. These authors found that 
participants prioritized tests with high clinical utility, meaning those with available 
options for treatment or prevention), followed by tests for conditions with high 
prevalence in the target population (Severin et al., 2013). While these studies 
demonstrate the utility of best worst scaling in eliciting preferences from both patients 
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and healthcare providers, this method has not yet been applied to assessing priorities 
within the counseling session from the provider perspective. Understanding the choices 
that genetic counselors make when faced with complicated discussions in a limited time 
may help to identify areas that contribute most to feelings of discomfort surrounding 
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PART 2: MANUSCRIPT 1 
 
Challenges to Informed Consent for Genomic Sequencing:  
a Systematic Literature Review 
Abstract 
Despite enthusiasm surrounding genomic sequencing as a clinical diagnostic and 
research tool, professionals and patients have voiced trepidation about the breadth of 
results and the uncertainties inherent to this technology. These concerns are particularly 
relevant to the process of consenting individuals to undergo sequencing. Yet the specific 
challenges and whether they may pose barriers to informed consent have not been well 
delineated. To address this gap, we conducted a systematic literature review to generate 
an inventory of evidence-based challenges to informed consent for genomic sequencing. 
A search of the peer-reviewed literature in PubMed, Scopus, Web of Science, EMBASE 
and Cochrane databases yielded 294 distinct abstracts. Abstracts were eligible for 
inclusion if published from January 1, 2010, to February 28, 2017, written in English, and 
reporting quantitative or qualitative primary data from patients, research participants or 
professionals in a research or clinical setting. Eleven papers met our inclusion criteria, 
and qualitative meta-analysis of data across studies yielded 17 distinct challenges. The 
three most common challenges were: conveying the possibility of secondary findings; 
communicating the limitations of sequencing; and prioritizing the abundance of 
information. The results of our meta-analysis identified barriers to effective patient-
centered communication that can be used to inform development of interventions to 
enhance the effectiveness of professional endeavors to consent individuals to genomic 
sequencing. Next steps following the systematic review may include assessment of the 
priorities among these consent challenges and strategies to address them.   
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Introduction 
Genomic sequencing, primarily exome sequencing, has increasingly been 
incorporated into clinical practice and research studies to identify disease-causing and 
risk-modifying variants throughout the genome. While there is much enthusiasm about 
the diagnostic potential of this new technology, concerns surrounding its integration have 
been voiced by clinicians, researchers and patients (Biesecker & Green, 2014; Farwell et 
al., 2014; Yang et al., 2014; Boland et al., 2015; Middleton et al., 2016). The breadth of 
sequencing represents a paradigm shift from traditional genetic testing that has targeted 
specific genes based on phenotype and familial risk assessment, as variants may now be 
identified independently of clinical indications (Hooker et al., 2014; Ayuso et al., 2013). 
The wide scope of possible results due to evolving methods for data interpretation poses 
particular challenges to achieving informed consent. Thus, an evidence-based 
understanding of which elements of the informed consent process are most challenging 
for patients to deliberate can help providers seek opportunities to improve their approach 
to patient engagement and the obtainment of meaningful consent.      
Broadly, informed consent for sequencing requires an understanding of the types 
of findings that may arise and the plan for managing and disclosing these results 
(Presidential Commission for Bioethics, 2012, 2013; van El et al., 2013). Despite calls 
for the development of best practice standards, considerable heterogeneity remains in the 
specific content and level of detail provided by genetic counselors and practitioners when 
obtaining consent (Fowler et al., 2017). For example, content analysis of consent 
documents from nine exploratory sequencing studies revealed evidence for significant 
variability in the descriptions of risks and benefits and in the categorization of potential 
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result types (Henderson et al., 2014). In addition to the wide range in content and detail, a 
study of self-reported pre-test counseling practices demonstrated that the communication 
style and length of time in which providers obtain consent were also highly variable 
(Arora et al., 2016).   
As genomic sequencing enters clinical care more broadly, healthcare 
professionals across disciplines have an opportunity to play a critical role in deliberating 
patient psychosocial and informational needs as part of the informed consent process. 
Efforts to achieve informed choice will require attention to communication and 
counseling strategies (Austin et al., 2014, deHaes et al. 2009). Despite experience 
consenting patients and parents of affected children to genetic testing, commentators have 
recognized the challenges faced by genetic counselors and researchers in communicating 
the complexity and uncertainty of potential results from genomic sequencing (Kost et al. 
2017; Roche et al., 2015). Concurrently, patients and participants approach testing 
decisions with a wide range of concerns surrounding the psychosocial impact of potential 
results and worries about privacy and genetic discrimination (McGowan et al. 2013; 
Robinson et al. 2016). Frustrations may arise when the consent process does not 
adequately address these decisional factors. Specifically, parents of affected children 
have expressed a need for increased emphasis on discussion of ways in which potential 
results may influence treatment and daily life (Rosell et al. 2016; Krabbenborg et al. 
2016). 
A systematic characterization of data from both the patient and counselor research 
literatures is key to understanding, and ultimately improving, the consent process for 
genomic sequencing. We carried out a systematic review of the literature that aimed to: 
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(1) characterize the nature and scope of challenges to the informed consent process as 
experienced by healthcare provides, researchers, patients and genomic study participants; 
(2) conduct a qualitative meta-analysis of the challenges inventoried; and (3) contribute 
evidence to guide future studies on barriers to informed consent. Determining the state of 
the science on challenges from multiple perspectives can inform the training and practice 





A comprehensive search of the electronic literature from January 1, 2010, to 
February 28, 2017, was conducted in PubMed, EMBASE, Scopus, Web of Science and 
Cochrane databases using the following combinations of key search terms (1) ("genome 
sequencing") OR "exome sequencing") OR "next generation sequencing") AND 
"informed consent"; and (2) ("genome sequencing") OR ("exome sequencing") OR "next 
generation sequencing"))) AND "genetic counseling") AND "barriers".  All generated 
citations were collected and imported into EndNote for review.  
Inclusion and Exclusion Criteria 
Peer-reviewed papers were eligible for inclusion if they were: (1) written in 
English; (2) published in 2010 or later; (3) quantitative or qualitative studies containing 
primary data from patients, research participants or healthcare providers; and (4) 
pertaining to the informed consent process for genomic sequencing in a research or 
clinical setting.     
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Abstracts that did not meet inclusion criteria were classified into exclusion 
categories prior to full manuscript review. Exclusion categories included papers that 
were: (1) published prior to 2010; (2) pertaining to prenatal testing or newborn screening; 
(3) ethics perspectives or thought pieces; (4) guidelines or policy statements; (5) review 
papers; (6) molecular technology or diagnostic case studies; (7) regarding other types of 
genetic testing; and (8) Miscellaneous – i.e. non-English language, excluded study type, 
not relevant to informed consent, post-mortem testing.   
Evaluation Method 
All abstracts were reviewed by the first author and classified into exclusion 
categories. Manuscripts that were not excluded during the first round of evaluation were 
obtained and reviewed in full to produce a final list of studies that met all inclusion 
criteria. Any ambiguity was reconciled between the authors.  
Quality Scoring 
 Quality was evaluated through utilization of an appraisal tool adapted from 
QualSyst by Paul and Colleagues (Kmet et al., 2004; Paul et al., 2015). All studies were 
evaluated on eight universal quality items assessing: clarity of objectives; study design; 
context; sampling strategy; participant selection; conclusion; and data collection/analysis. 
There were four additional items specific to study type; two were applied to qualitative 
studies and two were applied to quantitative studies. Mixed-methods studies were 
evaluated for all four additional items. Each item was assigned a score from 0-2 where 
0=no, 1=partial and 2=yes. Scores were totaled and divided by the maximum possible 
score of 20 (24 for mixed methods studies) and multiplied by 100 to generate a final 
quality rating. The minimum threshold for selection into the review was sixty-five, as this 
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value is between a liberal cut-point of 55 and a conservative cut-point of 75, as described 
by QualSyst (Kmet et al., 2004).  
Data Extraction 
Study characteristics extracted included: study type; country; study context 
(research or clinical setting); target population; sample size; and specific aims. 
Challenges to informed consent were first extracted verbatim, and redundancy was 
eliminated through the merging of synonymous items. Qualitative meta-analysis of 
findings across studies yielded the challenges that arose with greatest frequency.  
 
Results 
Study Selection and Characteristics 
 The systematic literature search generated 294 distinct abstracts after duplicates 
were removed. All abstracts were reviewed completely and evaluated for inclusion 
criteria and exclusion category.  Following the first round of evaluation, 252 papers were 
excluded (reasons for exclusion are detailed in Figure 1). The majority did not meet 
inclusion criteria for study type because they were ethics commentaries (n=73, 24.8%) 
and molecular studies or individual case reports (n=70, 23.8%). The remaining 42 papers 
were obtained and evaluated in full.  
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Figure 2.1: Systematic literature search flow. 
 
After final deliberation among the authors, eleven studies were eligible for 
inclusion in the analysis (Table 2.1). Of these eleven studies, the majority of these were 
qualitative in design (n=8, 72%); two were quantitative, and one employed a mixed-
methods approach. Clinical and research contexts were represented equally, with four 
studies exploring the informed consent process in a clinical setting, four in a research 
setting, and three targeting both clinical and research contexts. The majority of studies 
were conducted in the United States, with one study from Canada and two from the 
Netherlands. Quality scores for the included studies ranged from 70-90, with a mean 
score of 80. All quality scores were above the predetermined threshold of 65. 
Characteristics of the included studies are summarized in Table 2.1.  
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Table 2.1: Characteristics of included studies. 
 
The eleven studies included a total of 778 participants with a range of 15-35 
participants in the qualitative studies and 53-302 in the quantitative and mixed-method 
studies. A wide range of perspectives was captured in the included studies. Five studies 
targeted recipients of genetic services, including research participants and parents of 
children who underwent genomic sequencing, while four addressed the experience of 
healthcare professionals and experts in the field of genetic research. Two studies 
surveyed individuals from both groups. Some focused specifically on the informed 
consent process, while others addressed informed consent as part of a larger exploration 
of the implementation of genomic testing.  
Challenges 
 Despite the wide range of contexts and populations captured in the included 
studies, themes in the reported challenges to the informed consent process emerged 
repeatedly.  Following synthesis and meta-analysis of the extracted challenges, a list of 
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17 challenges was generated.  These items are summarized in Table 2.  The most 
prevalent challenges were: (1) conveying the possibility for secondary findings (n=8, 
72.7%);  (2) communicating limitations to the diagnostic potential of sequencing (n=7, 
63.6%); (3) prioritizing the abundance of information in the consent session and form 
(n=6, 54.5%); and (4) working effectively within time constraints of the counseling 
session (n=6, 54.5%).  Other reported challenges referenced logistical aspects of the 
testing process, including insurance coverage, result interpretation, and privacy 
protection.     
 
Table 2.2: Challenges to obtaining informed consent for genomic sequencing. 
 
Discussion 
 This systematic review identified seventeen distinct challenges to the informed 
consent process for genomic sequencing across clinical and research settings.  There was 
a striking degree of agreement in both the patient and provider literatures regarding the 
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most prevalent challenges, suggesting consistency in the elements of informed consent 
that influence perceived barriers to the implementation of sequencing.  The results of this 
review highlight the importance of refining both the content and process of consent in 
order to facilitate patients’ ability to make an informed choice about testing.  
Notably, uncertainty emerged as a major theme captured by nearly all of the 
reported challenges.  Uncertainty pervades genomics, and communicating the 
fundamental uncertainties surrounding the benefits and limitations of testing is essential 
to obtaining meaningful informed consent (Biesecker et al., 2015; Brenner et al., 2009). 
The role of uncertainty in the results of this review reflects the difficulty experienced by 
both patients and providers in approaching the consent process when the scope and utility 
of potential sequencing results is fundamentally uncertain.  Though healthcare providers 
cannot eliminate the uncertainty inherent to the technology, exploring its many sources 
and dimensions may help the recipients of genomic sequencing mitigate their perceptions 
and act on the results as appropriate (Han et al., 2017).  
The relative significance of the reported challenges can be evaluated based on 
their prevalence and the degree to which they influence patients’ ability to make an 
informed choice about testing.  An informed choice has been defined as “one that is made 
based on relevant knowledge, consistent with the decision-maker's values and 
behaviorally implemented” (Michie et al., 2002; Marteau et al., 2001). Under this 
definition, essential elements of the informed consent process are those that capture key 
aspects of testing related to patient attitudes and beliefs. The two most frequently 
acknowledged challenges fall into this category, as candidates for sequencing must 
evaluate their understanding of secondary findings and testing limitations in the context 
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of their health care goals.  Clinicians and researchers have a responsibility to engage in 
deliberations about these elements that explore patient values such as desire for 
information and tolerance of risk.  
A second category of challenges incorporates elements of consent that may 
facilitate patient decision-making, but are not fundamental to reaching an informed 
choice.  These include possible implications for relatives and changes to daily life.  
Though discussion of elements in this category may not be prioritized in written consent 
documents, the results of this review demonstrate that these aspects of testing are 
important to patients and to research participants.  Emphasizing these aspects of testing 
may help to engage patients in collaborative deliberation that is focused on relevant and 
concrete outcomes of sequencing.   
Notably, both patients and providers reported feeling overwhelmed by the volume 
of detailed technical information. This finding is consistent with communication studies 
demonstrating that genetic counseling sessions are often dominated by biomedical 
information, despite evidence that information sharing strategies lower in counselor 
verbal dominance and higher in active exchange facilitate improve understanding and 
satisfaction (Paul et al., 2015; Roter et al., 2006; Turbitt et al. 2017). Taken together, the 
data suggest that streamlining the amount of information discussed during the consent 
process would allow for more active deliberation of the testing aspects that are most 
relevant to patient decision-making. 
 The review also identified a number of procedural and administrative challenges, 
including time constraints on the counseling session and complications surrounding cost 
and insurance coverage. Addressing these challenges at an institutional level will allow 
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healthcare providers to focus on providing patients with a sufficient understanding of 
essential elements of sequencing so that they are able to make an informed choice 
consistent with their values. The results of this review provide a framework for 
characterizing challenges to the informed consent process for genomic sequencing and 
prioritizing which challenges to address.  
Study Limitations 
 The search parameters yielded studies capturing a wide range of perspectives and 
contexts, providing a comprehensive look at the state of informed consent for sequencing.  
However, it is still possible that relevant sources were overlooked by the search, 
particularly those that referenced informed consent as a secondary focus.  Relevant data 
may also have been missed due to the exclusion of non-English language papers and 
thought pieces emphasizing ethical arguments surrounding consent. We also chose to 
exclude papers regarding informed consent for other types of genetic testing, though 
these may have contained applicable data. Additionally, the small sample size of many of 
the included studies introduces potential bias, as they do not necessarily represent the 
views of a larger target population. Furthermore, studies that focused on the experience 
of early adopters of sequencing may not accurately reflect the current state of the field.  
Though all of the included studies met the predetermined quality threshold, the 
heterogeneity of study methods could impact the validity of the overall results of the 
review. 
Implications for Research and Practice 
 There are many challenges inherent to both the content and process of obtaining 
informed consent for genomic sequencing.  In developing more effective consent 
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protocols, clinicians and researchers should first focus on addressing challenges that are 
essential to patients’ ability to make an informed choice by ensuring understanding of the 
potential result outcomes and limitations of testing. Providers can then work towards 
incorporating more complete secondary information as needed for patients making a 
testing decision.  A tailored, stepwise process of this nature is consistent with proposed 
models of tiered consent that advocate for the communication of essential information 
followed by variable relevant information as needed to facilitate individualized patient 
understanding and informed choice (Bradbury et al., 2015; Bunnik et al., 2013). 
 Formalizing practices of providing less biomedical information and encouraging 
more dialogue about individually relevant aspects of testing could help to further develop 
a more effective approach to informed consent (Bernhardt et al., 2015; Wynn et al., 
2016). Additionally, providers should take advantage of opportunities to directly address 
sources of uncertainty throughout the consent process. This focus could potentially 
mitigate negative effects of discomfort associated with uncertainty and help patients to 
reframe uncertainty more positively as a source of hope (Biesecker et al., 2015).  
 This systematic review provides a foundation for future studies investigating 
challenges to implementing genomic sequencing in research and clinical care.  Future 
research could aim to design and test consent protocols that focus on active deliberation 
with limited technical information.  It would also be valuable for researchers to examine 
differences in provider and patient perspectives more fully, as this review found a large 
amount of agreement about general challenges. The results of this review directly 
contributed to the development of a best worst scaling experiment designed to assess 
genetic counselors’ perceptions of the greatest challenges to the informed consent process 
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among those identified from this review. This line of research will help to clarify how the 
challenges reported in the literature influence consent practice currently, and to improve 
training to target these issues specifically. 
 
Conclusion 
 This systematic literature review identifies 17 distinct challenges to the informed 
consent process for genomic sequencing as experienced by patients and healthcare 
providers.  The results highlight the importance of addressing sources of uncertainty; 
engaging in dialogue about elements of testing that are essential to informed choice; and 
streamlining the presentation of complex technical information. This characterization of 
challenges to the informed consent process for genomic sequencing provides a 
foundation for future research as well as a framework for the ongoing development of 
consent practice and training for practitioners. 
  
Acknowledgements 
We would like to thank Barbara Brandys, NIH librarian, for her help in designing 






Appelbaum, PS, Waldman CR, Fyer A, et al. Informed consent for return of incidental 
findings in genomic research. Genet Med, 2014; 16(5): 367-373.  
 
Arora S, Haverfield, E, Richard, G, Haga, SB, Mills, R. Clinical and Counseling 
Experiences of Early Adopters of Whole Exome Sequencing. J Genet Couns 
2016; 25(2): 337-343. 
 
Austin, J, Semaka, A, Hadjipavlou G, Conceptualizing genetic counseling as 




Ayuso C, Millan, JM, Mancheno M, Dal-Re R, Informed consent for whole-genome 
sequencing studies in the clinical setting: proposed recommendations on essential 
content and process. Eur J Hum Genet 2014; 21(10): 1054-1059. 
 
Bergner, AL, Bollinger, J, Raraigh KS, et al. Informed consent for exome sequencing 
research in families with genetic disease: the emerging issue of incidental 
findings. Am J Med Genet, 2014; 164A(11): 2745-2752. 
 
Bernhardt, B, Roche MI, Perry DL, Scollon SR, Tomlinson AN, Skinner D. Experiences 
with obtaining informed consent for genomic sequencing. Am J Med Genet A, 
2015; 167A(11): 2635-2646. 
 
Biesecker BB, Klein W, Lewis K, et al. How do research participants perceive 
“uncertainty” in genomic sequencing? Genet Med 2015; 16(2): 977-980. 
Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J 
Med 2014; 370:2418-2425. 
 
Boland PM, Ruth K, Matro JM, et al. Genetic counselors' (GC) knowledge, awareness, 
understanding of clinical next-generation sequencing (NGS) genomic testing. Clin 
Genet 2015; 88(6): 565-572. 
 
Bradbury AR, Patrick-Miller L, Long J, et al. Development of a tiered and binned genetic 
counseling model for informed consent in the era of multiplex testing for cancer 
susceptibility. Genet Med 2015; 17(6): 485-492. 
 
Brenner LH, Brenner AT, Horowitz D. Beyond informed consent: educating the patient. 
Clin Orthop Relat Res 2009; 467(2): 348-51. 
 
Bunnik EM, Janssens ACJW, Schermer MHN. A tiered-layered-staged model for 
informed consent in personal genome testing. Eur J Hum Genet 2013; 21(6): 596-
601. 
 
deHaes H, Bensing J. Endpoints in medical communication research, proposing a 
framework of functions and outcomes. Patient Educ Couns 2009; 74(3): 287-294. 
 
Farwell KD, Shahmirzadi L, El-Khechen, D, et al. Enhanced utility of family-centered 
diagnostic exome sequencing with inheritance model–based analysis: results from 
500 unselected families with undiagnosed genetic conditions. Genet Med 2015; 
17(7): 578-586. 
 
Fowler SA, Saunders CJ, Hoffman MA. Variation among consent forms for clinical 
whole exome sequencing. J Genet Couns 2017; e-pub ahead of print 8 July 2017; 
doi: 10.1007/s10897-017-0127-2. 
 38 
Han PKJ, Umstead KL, Bernhardt B, et al. A taxonomy of medical uncertainty in clinical 
genome sequencing Genet Med 2017; e-pub ahead of print 19 January 2017; 
doi:10.1038/gim.2016.212. 
 
Henderson, GE, Wolf, SM, Kurczynski KJ, et al. The challenge of informed consent and 
return of results in translational genomics: empirical analysis and 
recommendations. J Law Med Ethics 2014; 42(3): 344-355. 
 
Hooker G, Ormond, KE, Sweet K, Biesecker BB. Teaching genomic counseling: 
preparing the genetic counseling workforce for the genomic era. J Genet Couns 
2014; 23(4): 445-451. 
 
Kmet LM, Lee RC, and Cook LS, Standard quality assessment criteria for 
evaluatingprimary research papers from a variety of fields. 2004, Alberta 
Heritage Foundation for Medical Research Edmonton. 
 
Kost, RG, Poppel SM, Coller BS, Informed consent for next-generation nucleotide 
sequencing studies: aiding communication between participants and investigators. 
J Clin Transl Sci 2017; 1(2): 115-120.new 
 
Krabbenborg, L, Vissers, LE, Schieving J, et al. Understanding the Psychosocial Effects 
of WES Test Results on Parents of Children with Rare Diseases. J Genet Couns 
2016; 25(6): 1207-1214. 
 
Krabbenborg L, Schieving J, Kleefstra T, et al. Evaluating a counselling strategy for 
diagnostic WES in paediatric neurology: an exploration of parents' information 
and communication needs. Clin Genet, 2016; 89(2): 244-250. 
 
Levenseller BL, Soucier DJ, Miller VA, Harris D, Conway L, Bernhardt BA. 
Stakeholders' opinions on the implementation of pediatric whole exome 
sequencing: implications for informed consent. J Genet Couns, 2014; 23(4): 552-
565. 
 
Li KC, Birch PH, Garrett BM, MacPhee M, Adam S, Friedman JM. Parents' Perspectives 
on Supporting Their Decision Making in Genome-Wide Sequencing. J Nurs 
Sholarsh 2016; 48(3): 265-275. 
 
Machini K, Douglas J, Braxton A, Tsipis J, Kramer K, Genetic counselors' views and 
experiences with the clinical integration of genome sequencing. J Genet Couns 
2014; 23(4): 496-505.  
 
Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Exect, 2001; 
4(2): 99-108. 
 
McGowan ML, Glinka A, Highland J, Asaad G. Genetic patients’ perpectives on clinical 
genomic testing. Per Med 2013; 10(4): 339-347, 
 39 
  
Michie S, Dormandy E, Marteau TM. The multi-dimensional model of informed choice: 
a validation study. Patient Educ Couns 2002; 48(1): 87-91. 
 
Middleton A, Morley KI, Bragin E, et al. Attitudes of nearly 7000 health professionals, 
genomic researchers and publics toward the return of incidental results from 
sequencing research. Eur J Hum Genet 2016; 24(1): 21-29. 
 
Oberg, JA, Glade Bender JL, Cohn EG, et al. Overcoming challenges to meaningful 
informed consent for whole genome sequencing in pediatric cancer research. 
Pediatr Blood Cancer 2015; 62(8): 1374-1380.   
 
Paul J, Metcalfe S, Stirling L, Wilson B, and Hodgson J, Analyzing communication in 
genetic consultations—A systematic review. Patient education and counseling 
2015; 98(1): 15-33. 
 
Presidential Commission for the Study of Bioethical Issues. Privacy and progress in 
whole genome sequencing 2012, Report of the Presidential Commission. 
 
Presidential Commission for the Study of Bioethical Issues. Anticipate and 
Communicate: Ethical management of incidental findings in the clinical, 
research, and direct-to-consumer contexts 2013, Report of the Presidential 
Commission. 
 
Rigter T, van Aart CJ, Elting MW, Waisfisz Q, Cornel MC, Henneman L. Informed 
consent for exome sequencing in diagnostics: exploring first experiences and 
views of professionals and patients. Clin Genet 2014; 85(5): 417-422. 
 
Robinson JO, Carroll TM, Feurman LZ, et al. Participants and study decliners’ 
perspectives about the risks of participating in a clinical trial of whole genome 
sequencing. J Empir Res Hum Res Ethics 2016; 11(1): 21-30.  
 
Roche MI, Berg, JS, Incidental findings with genomic testing: implications for genetic 
counseling practice. Curr Genet Med Rep 2015; 3(4): 166-176. 
 
Rosell, AM, Pena LD, Schoch K, et al. Not the end of the Odyssey: parental perceptions 
of whole exome sequencing (WES) in pediatric undiagnosed disorders. J Genet 
Couns 2016; 25(5): 1019-1031.  
 
Roter D, Ellington L, Erby LH, Larson S, Dudley W. The genetic counseling video 
project: models of practice. Am J Med Genet C Semin Med Genet 2006; 142C(4): 
209-220. 
 
Tolusso LK, Collins K, Zhang X, Holle JR, Valencia CA, Myers MF. Pediatric Whole 
Exome Sequencing: an Assessment of Parents' Perceived and Actual 
Understanding. J Genet Couns 2017; 26(4): 792-805. 
 40 
 
Tomlinson, AN, Skinner D, Perry DL, Scollon SR, Roche MI, Bernhardt BA. "Not Tied 
Up Neatly with a Bow": Professionals' Challenging Cases in Informed Consent 
for Genomic Sequencing. J Genet Couns 2016; 25(1): 62-72. 
 
Turbitt E, Chrysostomous PP, Heidlebaugh A, Nelson LM, Biesecker BB. A randomized 
controlled study of a consent intervention for participating in an NIH genome 
sequencing study. Manuscrip submitted for publication; 2017. 
 
van El CG, Cornel MC, Borry P, et al. Whole genome sequencing in health care: 
Recommendations of the European Society of Human Genetics. Eur J Hum Genet 
2013; 21(6): 580-584. 
 
Wynn, J. Genomic testing: a genetic counselor’s personal reflection on three years of 
consenting and testing. J Genet Couns 2016; 25(4): 691.697.                                             
 
Yang Y, Muzny DM, Xia, F, et al. Molecular findings among patients referred for 





















PART THREE: MANUSCRIPT 2 
 
Challenges to Informed Consent for Exome Sequencing:  
a Best Worst Scaling Experiment 
 
Abstract 
 As exome sequencing expands as a diagnostic tool, patients and providers have 
voiced concerns about the breadth and scope of potential results.  Particularly, genetic 
counselors perceive challenges to prioritizing complex information during informed 
consent sessions. This study aimed to understand how genetic counselors approach the 
consent process and weigh the relative importance of its many components. Best-worst 
scaling methodology was used to characterize how genetic counselors prioritize essential 
elements of informed consent specific to exome sequencing. The development of a best-
worst scaling experiment was informed by a systematic review of the literature and two 
focus groups. Choice sets were created using a balanced incomplete block design, where 
participants selected the most and least important attribute in each choice set. Mediation 
analyses were used to assess whether responses were associated with previous experience 
ordering exome sequencing, perceived efficacy in consenting patients, and counselors’ 
tolerance for ambiguity. An online survey was distributed to all full members of the 
National Society of Genetic Counselors and completed by 342 recipients. Data were 
analyzed using mean best-worst scores to summarize the number of times each attribute 
was selected as most and least important. Ranking of best-worst scores suggests that 
genetic counselors prioritize collaborative decision-making, assessing patient 
understanding and managing expectations for results, with the least emphasis placed on 
discussing technological complexities. Stratified analyses by paired t-tests found that 
counselors with more experience ordering exome sequencing, and those reporting higher 
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perceptions of patients’ ability to manage information were significantly more likely to 
prioritize discussion of variants of uncertain significance (p<0.05). Results convey 
counselors’ prioritization of individual patient needs for obtaining informed consent for 
exome sequencing, and that professional characteristics and attitudes may influence 
preemptive discussion of uncertain results. Future studies are needed to determine how 
counselors’ consent practices exhibit these priorities. 
 
Introduction: 
 Since its introduction as a research and more recently, a clinical tool, exome 
sequencing has been met with both enthusiasm and trepidation. Despite the excitement 
surrounding diagnostic potential, there has been much debate about how to manage 
secondary findings, evolving result interpretation, and variants of uncertain significance 
(VUS) (Bertier et al., 2016; Green et al., 2013). Rigorous informed consent is essential to 
ensure that patients and parents accurately understand the limitations and potential 
uncertainties of genomic sequencing (Biesecker & Green, 2014, Bernhardt et al., 2015). 
Broadly, informed consent must address expected outcomes of testing including the type 
and likelihood of results that will or will not be returned, as well as the risks, benefits, 
limitations, alternatives to testing and potential implications for relatives (ACMG Board 
of Directors, 2013; Ayuso et al., 2013).  
The unpredictable nature and broad scope of potential results challenge the 
paradigm of traditional informed consent procedures that have been applied to more 
targeted genetic testing (Hooker et al., 2014; Bernhardt et al., 2015).  Uncertainties 
pervade exome sequencing, as the majority of variants identified are currently classified 
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as VUS and lack clear-cut management recommendations (Han et al., 2017; Bertier et al., 
2017).  A lack of identification of any pathogenic variants is nuanced and generally 
treated as provisional given the evolving understanding of interpretation (Skinner et al. 
2016). These challenges are particularly salient in the pediatric setting where children 
undergoing a diagnostic workup have the potential to learn information about risk for 
unrelated adult onset conditions that could profoundly influence developing self-identity 
(Miller et al., 2017; Werner-Lin et al., 2016). Current guidelines and laboratory practices 
provide an option for patients to opt-out of receiving medically actionable secondary 
findings (Kalia et al., 2017; O’Daniel et al., 2017). This decision must be made prior to 
ordering testing, and is often considered during the informed consent session. These 
choices can be complicated by the involvement of children in providing assent, and the 
possible implications for parents and relatives when trio testing is ordered (Levenseller et 
al., 2014; Bernhard et al., 2015). Furthermore, families of children affected with 
developmental delays and/or rare undiagnosed conditions often have high expectations 
for the diagnostic capability of sequencing that may inhibit their ability to fully accept the 
limitations of testing (Anderson et al., 2016; Tomlinson et al., 2016).   
Most often, genetic counselors are the professionals consenting adults and parents 
to genomic sequencing (Machini et al. 2014; Egalite et al. 2014). They report concerns 
about the amount and complexity of information included in consent documents and 
professional guidelines which may impact how they communicate these concepts 
(Bernhardt et al., 2015; Rigter et al., 2014). Studies of communication about genetic 
testing have found that professional presentation of biomedical information often 
dominates the interaction, leading to limited patient participation (Paul et al., 2015; Roter 
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et al., 2006). Despite clear intentions and attempts to engage patients, discussions of 
exome sequencing have also been dominated by provider provision of genomic education 
(Walser et al., 2017; Levenseller et al., 2015). This pattern may explain parents’ 
reporting that pretest counseling underemphasizes discussions of the aspects of testing 
they value, such as how results could impact daily life (Krabbenborg et al., 2016). As 
genetic counselors have become more familiar with informational content of genomic 
sequencing, there has been a reported shift towards more interactive consent sessions 
with lower prioritization of technical information (Bernhardt et al., 2015; Wynn, 2016). 
This suggests that experience with exome sequencing may lead to adjusted consent 
strategies.  
 To capture the many factors that may affect the process of achieving informed 
consent for exome sequencing, this study was informed by the Theory of Motivated 
Information Management (Afifi & Weiner, 2004). This theory describes an interactive 
process in which information providers make decisions about communication based on 
assessments of the information recipient and projected outcomes of the interaction. 
Particularly relevant to this study are the concepts of communication efficacy, an 
individual’s perception of their own ability to share information effectively, and target 
efficacy, perceptions of the recipient’s willingness and ability to manage information 
(Afifi & Weiner, 2004). Higher levels of both concepts have been associated with greater 
intentions to share information directly (Hovick, 2014; Fowler & Afifi, 2011; Dillow & 
Labelle, 2014). This theory was used to frame a study to answer whether communication 




 To assess these relationships, information management strategies must be 
operationalized quantitatively. Best-worst scaling (BWS), a type of conjoint analysis 
traditionally used in marketing research, has recently been appropriated into health care 
research as a method for evaluating stakeholder priorities (Cheung et al., 2016; Flynn et 
al., 2007; Mulbacher et al., 2016). BWS relies on the basic assumptions that individuals 
make decisions to maximize utility, and that a component of utility is not consciously 
accessible (Thurstone 1927, McFadden, 1974). As such, BWS aims to elicit underlying 
valuations by gathering data about choices made at the extreme ends of preference 
(Louviere & Flynn, 2010). This approach is more reliable in predicting outcomes than 
traditional ranking systems as it requires participants to select only the best and worst 
items in a series of choice sets, thereby eliminating the need to make indiscriminate 
choices about midrange items (Louviere et al., 2007; Peay et al., 2015; Edem & Rigby, 
2013). Previous applications of BWS in the context of genetics research have explored 
perceived barriers to personalized medicine and prioritized outcomes of genetic testing 
(Najafzadeh et al., 2011; Severin et al., 2013). These authors found that healthcare 
providers placed the highest value on genetic tests with high clinical utility, defined as 
those with associated medical interventions, and tests for highly prevalent conditions 
(Severin et al., 2013).  Physicians also consider the type of testing, their training and 
professional guidelines when assessing the feasibility of incorporating genetic testing into 
their practice (Najafzadeh et al., 2011). As new genomic technologies enter clinical care, 
BWS provides a valuable tool for understanding preferences to guide implementation and 
policy.  
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Previous research has focused on identifying the essential elements of informed 
consent for exome sequencing, but to our knowledge have not explored how genetic 
counselors prioritize these items in consent sessions with patients (Ayuso et al., 2013; 
Presidential Commission for Bioethics, 2013).  Gaining a clearer understanding of 
genetic counselors’ approach to obtaining consent can inform the development of more 
standardized practices and identify potential discordance between patient and provider 
priorities. This study used a Best-Worst scaling experiment to understand how genetic 
counselors prioritize elements of informed consent when presenting options for exome 
sequencing in a pediatric clinical setting. The second aim was to explore the relationship 
between prioritization decisions and counselor factors such as experience with exome 
sequencing, tolerance for uncertainty, communication efficacy and target efficacy. We 
hypothesized that genetic counselors reporting more experience with exome sequencing 
and higher communication efficacy would place less emphasis on discussing the 
technical aspects of sequencing, and would prioritize discussions about outcomes of 
testing and decision-making.     
 
Methods 
Best-Worst Scaling Task Design 
Consideration and design of a best-worst scaling (BWS) experiment was in 
accordance with standards put forth by the ISPOR checklist for conjoint analysis (Bridges 
et al., 2011). Best-worst scaling was selected based on the exploratory nature of the 
research question, and the added benefit of collecting data about the least prioritized 
aspects of informed consent. Three types of BWS methodology have been described that 
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use the same underlying principles to capture differing aspects of participant choice 
(Louviere et al, 2007). Based on the current structure of informed consent components, 
BWS Case 1 (object case) was selected. BWS Case 1 provides information about the 
relative ranking of individual attributes, and does not include sublevels within each item 
like BWS Cases 2 and 3. Across all types of best-worst scaling studies, attributes should 
contribute separately to the underlying “utility” construct and must be comparable to each 
other (Mulbacher et al., 2016; Coast et al., 2012).  
Attributes were proposed using evidence from the published literature as well as 
qualitative analysis of focus group data to encompass all relevant aspects of informed 
consent for exome sequencing (Bridges et al., 2011). Attribute development was 
conducted in a two-step process, starting with the conceptual delineation of each item 
followed by the refinement of meaningful language (Coast et al, 2012). A preliminary list 
of seventeen attributes capturing challenges to informed consent for genomic sequencing 
was developed from a systematic review of the literature published from January 2010 to 
February 2017 (findings presented in Part 1).   
Two focus groups were subsequently conducted with six genetic counselors in 
total, who all reported previous experience with exome sequencing. Each focus group 
was facilitated by the student investigator using an interview guide in conjunction with 
paper forms listing the preliminary attributes. Focus group participants were asked to 
draw upon their clinical experience to provide oral and written feedback on the 
preliminary elements, and to suggest additional elements that may not have been 
captured. Focus group participants generally endorsed the preliminary elements, and 
suggested removing select attributes due to redundancy and dividing one attribute that 
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captured two concepts into two distinct elements. These results were incorporated to 
devise the final list of elements. 
The final list of eleven attributes was organized into choice sets using a Balanced 
Incomplete Block Design (BIBD) so that each attribute appears the same number of times 
and co-appears with all other attributes evenly (Street & Street, 1987; Louviere et al., 
2007). The BIBD used in this study was generated using the “support.BWS” package for 
R statistical software (Aizaki, 2017; other R how to). In this design, all attributes appear 
five times and participants are presented with eleven choice sets, each containing five 
items. After choice sets were constructed, the attributes were randomized within each 
choice set to control for potential bias from ordering effects. The order in which choice 
sets were presented was randomized as well. For each choice set, participants were asked 
to select the most and least important attribute. A sample choice set is presented in Figure 
3.1. 
Figure 3.1: Sample choice set presenting five attributes. 
Study Instrument Design 
 In addition to the best-worst scaling experiment, the survey assessed participant 
characteristics, professional experience and attitudes towards informed consent for exome 
sequencing. Demographic characteristics included age, gender, race and ethnicity, 
geographic location, years in practice, practice specialty, and experience ordering exome 
sequencing.  Tolerance for uncertainty was measured using the modified Tolerance for 
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Ambiguity scale, a 7-item measure capturing the degree to which an individual is 
comfortable approaching uncertain situations (Geller et al, 1993). This scale was 
previously validated for use in the context of genetic testing. A 6-item knowledge check 
was adapted from the whole exome sequencing domain of the UNC Genomic Knowledge 
Scale to assess understanding of relevant basic concepts (Langer et al., 2017). This scale 
was originally designed for a patient population; thus, it was expected that most 
participants would answer correctly allowing responses to be used as a validity check for 
the sample.  
 A hypothetical pediatric clinical scenario was designed to provide a standardized 
context for the best-worst scaling tasks. The scenario provided a general indication for 
pediatric exome sequencing, but did not offer detailed clinical or psychosocial 
information about the hypothetical patient. In line with previous work using hypothetical 
patients, the scenario was written to maximize verbal immediacy, the degree of direct 
communication between the source and receiver of information, as well as temporal 
proximity, the portrayal of a situation as having immediate consequences (Persky et al, 
2007). Communication efficacy and target efficacy were assessed in the context of the 
hypothetical scenario with four items each rated using a 7-point Likert scale. These were 
modeled on instruments validated in previous studies informed by the Theory of 
Motivated Information Management (Hovick et al., 2014; Fowler & Afifi, 2011).    
Prior to initiation of the BWS experiment, attributes were presented individually 
and participants were asked to report the degree to which they perceived each attribute to 
be challenging using a sliding scale from 0 to 100. The BWS tasks required participants 
to select the single ‘most important’ and ‘least important’ elements of informed consent 
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in each five-attribute choice set. A selection had to be made before advancing to the next 
choice set. At the end of the survey participants had the opportunity to provide open 
ended feedback about their experiences with exome sequencing and completing the BWS 
study. The online survey was assembled and formatted using Survey Monkey. Four 
genetic counselors employed in a variety of settings pilot tested the instrument, and 
feedback was incorporated prior to survey finalization.   Modifications included 
providing more detailed instructions before introducing the best worst scaling tasks and 
presenting explanations of each attribute below the choice sets in a standardized order.  
Recruitment and Participants 
 Eligible participants were full members of the National Society of Genetic 
Counselors (NSGC) practicing in any specialty or setting in the United States or Canada. 
Previous experience ordering exome sequencing was not required. Study invitations were 
sent via the NSGC email listserv to over 4,040 genetic counselors, and a reminder email 
was sent two weeks later. Participants were offered a $10 Amazon gift card for 
completing the survey. Both the focus group interview study and the anonymous survey 
were determined to be exempt from IRB approval by the NIH Office of Human Subject 
Research Protection (OHSRP). The survey was assembled and distributed via Survey 
Monkey. 
Target sample size was estimated using G*Power 3 at a significance level of 0.05 
and a power level of 0.80 (Faul et al, 2007). Effect size was set at 0.06, a conservative 
estimate based on the correlation between efficacy scores and information management 
decisions reported in previously published studies (Fowler & Afifi, 2011; Afifi & 
Weiner, 2006). Based on these parameters, a target sample of 220 participants was sought 
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to sufficiently power the study. This target sample size is consistent with requirements for 
conjoint analysis (de Bekker Grob et al., 2015).  
Data Analysis 
 Best-worst scaling data was analyzed using a count based approach. In this 
method, the relative importance of each attribute is reported as a Best-Worst (BW) score 
calculated by subtracting the total number of times that the item was selected as the least 
important from the number of times that it was chosen as the most important (Flynn et 
al., 2007; Peay et al, 2015).  Total BW scores were then divided by the number of times 
that each attribute was available to be chosen. This generates a mean BW score for each 
attribute that can be used for standardized ranking. Individual BW scores were also 
calculated for every participant, and ranged from -5 to +5 for each attribute. Dividing the 
individual BW scores by five generated individual mean scores for each attribute that 
were then used to calculate standard errors for the overall mean BW scores. Standardized 
mean BW scores were rank ordered and reported with standard deviations and 95% 
confidence intervals. 
There are a variety of methods for analysis of BWS data, this method was 
primarily selected because it is conducive to running stratified analyses examining one 
variable at a time. Additionally, standardized mean scores for each attribute can be 
compared to each other and variables do not need to be coded (Peay et al., 2014).  
Despite its relative simplicity, the count-based approach has been shown to yield valid 
object measures comparable to those derived with more complex regression-based 
models such as conditional logit and linear probability (Flynn et al, 2007; Louviere & 
Flynn, 2010). Thus, this method provides valid and reliable results, but is still 
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conceptually accessible to the target population of genetic counselors and clinical policy 
makers. 
Four stratified analyses were performed among groups that differed by level of 
previous experience with exome sequencing, tolerance for ambiguity, communication 
efficacy and target efficacy. Mean BW scores were generated for all attributes in each 
group, and two tailed t-tests were conducted to assess whether between-group differences 
for any of the attributes were statistically significant (Peay et al., 2015). Demographic 
data was reported using descriptive summary statistics for the whole population and 
separating based on degree of experience with exome sequencing. The probability test 
function in Stata was used to test whether characteristics varied significantly between the 
two groups.  
 
Results 
 A total of 375 genetic counselors initiated the survey, and 342 completed the 
study in its entirety. Incomplete surveys were excluded, and the 342 complete responses 
were used in the analysis. 97.6% of participants answered all items on the knowledge 
scale correctly, supporting validity of the sample. Participants reported a wide range of 
experience with exome sequencing; 7.6% had ordered 50 or more exome sequencing 
tests, 12% had ordered 30-49, 19.8% had ordered 10-29, the majority (38.6%) had 
ordered sequencing 1-9 times, and 22% had never ordered it. The sample was split into 
two groups based on experience, the ‘less experienced’ group included those who had 
ordered exome sequencing zero to nine times (60.8%), and 39.2% were in the ‘more 
experienced’ group that reported ordering sequencing 10 times or more. 
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 Table 3.1 summarizes respondent characteristics. Some participants declined to 
answer select demographic questions. The majority of participants were Caucasian 
females who reported working primarily in a clinical setting. These demographic findings 
matched that of the larger membership of NSGC and the target population of genetic 
counselors (PSS, 2016). The sample included genetic counselors in a variety of 
specialties, with the largest proportion working in pediatrics (31.8%). Most of the 
respondents had been in practice for less than five years (62.3%).  Tolerance for 
ambiguity (TFA) varied among the sample, but generally trended towards lower TFA 
with a mean score of 20.0, ranging from 7 (highest TFA) to 31 (lowest TFA).  
Communication efficacy and target efficacy were generally high across the whole 
sample, with a mean score of 6.1 and 5.0 out of 7, respectively. Scores on these two 
efficacy scales were not highly correlated (R=0.44).    
When separated by experience with exome sequencing, there were significant 
differences in setting and specialty. Those in the less experienced group were 
significantly more likely to work in a prenatal, cancer or laboratory setting, while 
pediatric genetic counselors made up most of the more experienced group (p=<0.01). 
These differences were expected and are consistent with current clinical use of exome 
sequencing (Bertier et al., 2017). There was also a statistically significant difference in 
perceptions of both communication and target efficacy, as counselors with more 
experience reported significantly higher mean efficacy scores for both domains 
(p=<0.01). There were no significant differences in tolerance for ambiguity or other 
demographic characteristics between the two groups. 
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Prioritized Elements of Informed Consent 
  Before starting the best-worst scaling tasks, participants rated the degree to which 
they found each attribute challenging on a sliding scale from zero to one hundred. The 
top three most challenging elements were: “managing patient expectations for results” 
(mean 41.85), “assessing patient understanding” (36.39), and “describing technological 
complexities” (mean 34.98).  “Discussing implications for relatives” was rated as least 
challenging (24.72).   
Ranked mean BW scores with standard errors and 95% confidence intervals are 
presented in Table 3.2 and represented graphically in Figure 3.2. “Engaging patients in 
collaborative decision making” was endorsed as the most important element of obtaining 
informed consent (BW=0.596, SE=0.019). Participants also reported prioritizing 
“assessing patient understanding” (BW=0.584, SE=0.018) and “managing patient 
expectations” (BW=0.380, SE=0.018). The least important attributes were “discussing 
technical complexities” (BW=-0.812, SE=0.015) and “explaining evolving variant 
interpretation” (BW=-0.322, SE=0.018). “Explaining variants of uncertain significance” 
(BW=0.250, SE=0.014) was ranked as the midpoint, and this mean BW score was not 
statically significantly different from zero (95% CI: -0.034,0.02).  
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Table 3.2: Attributes ranked by relative importance with total BW scores, mean BW 




Figure 3.2: Attributes ranked by relative importance using mean Best-Worst scores.  
Bars represent standard errors.  
 
Stratified BWS analyses were conducted by experience with exome sequencing, 
communication efficacy, target efficacy and tolerance for ambiguity. Results of the 
stratified analyses with p-values from two-sided t-tests are summarized in Table 3.3. 
Significant differences were observed for the following attributes after stratifying by 
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Describing technological complexites
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Ranked Mean BW Scores
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experience with exome sequencing: “explaining variants of uncertain significance” 
(p=0.036), “conveying implications for relatives” (p=0.002) and “clarifying the meaning 
of a negative result” (p=0.00013). These differences are compared in Figure 3.3. The 
efficacy and TFA responses were divided into low and high groups based on the mean 
scores for each construct. Respondents in the high perceived target efficacy group ranked 
“explaining variants of uncertain significance” as significantly more important than those 
in the low target efficacy group (p=0.036). There were no significant differences in mean 





Table 3.3: Mean BW scores compared based on experience with exome sequencing, 
communication efficacy, target efficacy and tolerance for ambiguity. P-values represent 




Figure 3.3: Mean BW scores compared by experience ordering exome sequencing. 
 
Discussion 
Our results suggest that genetic counselors most highly value elements of the 
informed consent process that facilitate patient engagement and shared deliberation. 
Conversely, they rank discussing complex technical information and variant 
interpretation as least important. These findings were consistent among counselors with 
and without direct experience with exome sequencing, suggesting that these intentions 
are rooted in professional values rather than individual experience with genomic 
sequencing. The observed ranking favors elements of informed consent that increase 
patient participation and invite clarifying questions. Because these attributes focus on 
understanding personal preferences for testing, the stated priorities are also congruent 
with the definition of informed choice as a decision that is made and implemented with 
sufficient knowledge and supported by individual values (Michie et al., 2002). 
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Participants also highly rated the importance of managing expectations for potential 
results, an essential aspect of pretest counseling that may be challenging to convey 
(Skinner et al., 2017).  
 This study provides evidence for a unified view of intentions for approaching 
informed consent for exome sequencing. However, more research is needed to 
understand how these intentions translate into practice. Observations from a recent study 
of exome result return clearly demonstrated providers’ attempts to assess patient 
understanding, but found misunderstandings were not fully addressed and many of these 
sessions defaulted to information-heavy communication (Walser et al, 2017). Similarly, a 
study of methods used to facilitate child involvement in informed consent sessions found 
that most providers attempted to engage children, but did not fully utilize specific 
strategies such as starting the session with procedural information that is most likely to be 
salient to children (Miller et al., 2017).  Genetic counselors have a clear desire and 
intention to facilitate understanding and collaborative decision-making, and may benefit 
from training in specific communication strategies, such as teach back methods, to further 
implement counseling goals. These tools may be particularly beneficial when involving 
children or adolescents who may not be accustomed to participating in healthcare 
decisions (Werner-Lin et al., 2016).   
 Another major finding was that explaining variants of uncertain significance 
(VUS) was rated as significantly more important among respondents with more 
experience ordering exome sequencing and those with higher perceived target efficacy. 
Questions about the interpretation and communication of VUS results has been central to 
debates surrounding the utilization of exome sequencing, especially given that there is 
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currently a higher yield of VUS results than pathogenic variants (Bertier et al., 2017). 
Counselors with more experience ordering exome sequencing may be more acutely aware 
of the high probability of obtaining a VUS result, and this may motivate them to 
prioritize this discussion during informed consent. Along the same lines, more experience 
with exome sequencing may also lead to increased comfort with discussing uncertainty 
and providing anticipatory guidance prior to results disclosure. As part of these 
discussions, providers can help patients to frame VUS results in a productive manner as 
they may represent future possibilities for clarity and an opportunity for future partnering 
with the care team (Timmermans et al., 2016; Walser et al., 2017). 
In the cancer setting, VUS results have been associated with a moderate but 
significant increase in patient distress (Lumish et al.,2017). There is also evidence that 
some parents have difficulty conceptualizing the meaning of a VUS in the context of 
microarray testing (Kiedrowski et al, 2015; Reiff et al., 2012).  Knowledge that it can be 
challenging for parents to understand and adapt to the finding of a VUS could explain 
why participants with lower perceptions of target efficacy ranked explaining the 
possibility of uncertain results significantly lower than those in the high target efficacy 
group.  Genetic counselors with more experience ordering exome sequencing reported 
significantly higher perceptions of target efficacy, suggesting that target efficacy may 
mediate the relationship between experience and value placed on discussing variants of 
uncertain significance. While uncertainty cannot be eliminated from exome sequencing, 
providers have an opportunity to help patients understand differing sources of ambiguity 
and identify areas where they can attempt to find control in the face of uncertainty (Han 
et al., 2017).  These ideas may be particularly helpful if explored during pretest 
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counseling so that patients can begin to build a concept of uncertainty prior to receiving a 
result.   
Limitations 
 The findings of this study are limited by the fact that many participants did not 
have direct experience with exome sequencing.  As a result, the findings should be 
interpreted primarily as intentions rather than reported actions. More research is needed 
to understand how these intentions are implemented in practice.  Despite this limitation, 
responses from these participants helped to identify relevant differences between groups 
with differing levels of experience and mirrored current uses and prevalence of exome 
sequencing.  Additional limitations arise from the demographic homogeneity of the 
sample, though our respondents were highly representative of overall NSGC membership 
(PSS, 2016).  
There could also be limitations in the ability of utilized scales to fully capture the 
constructs of interest. Particularly, additional heterogeneity in perceived communication 
and target efficacy might have been identified if more items were included in these 
scales. Furthermore, tolerance for uncertainty is a complex construct encompassing a 
variety of cognitive and emotional reactions. A number of scales have been designed, 
though there is an observed lack of consistency and coherence across these measures 
(Hillen et al., 2017). The scale used in this study was selected because it has been 
previously validated for use with genetics professionals (Gellar et al., 1993).  However, 
we recognize that it may not have addressed the full spectrum of factors that contribute to 
an understanding of tolerance for uncertainty. 
 62 
Despite the rigorous attribute development process, it is possible that important 
concepts were not captured by the included items.  Inclusion of additional attributes could 
have provided more nuanced results.  Additionally, participants could have perceived 
conceptual overlap or clear superiority among some of the attributes leading to difficulty 
in making direct comparisons.  Meaning of each attribute could have been interpreted 
differently by individual participants, which would also have influenced responses.  
Future studies could gather additional information by using a similar method to survey a 
patient population. 
Practice implications 
 As exome sequencing becomes more widely used, patients may benefit from an 
increased understanding of sources of uncertainty as well as clarification of their attitudes 
towards uncertainty.  Acknowledgement of uncertainty should be included in the 
informed consent process, as uncertainty can be raised with any outcome of sequencing.  
Since many of the respondents had never ordered exome sequencing, the best-worst 
scaling task could have acted as a values clarification exercise to help participants begin 
thinking about what they find most challenging about exome sequencing and how they 
hope to approach these discussions in practice.  While this was not the primary aim of the 
study, secondary gains of this nature could increase overall awareness of the 
complications introduced by exome sequencing the need to prioritize aspects of informed 
consent.  These results suggest that genetic counselors strongly value collaborative 
decision-making and ensuring patient understanding.  These priorities should inform 
future training initiatives that prepare healthcare providers across all disciplines to 
incorporate exome sequencing into their clinical and research practices. 
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APPENDIX A: Recruitment Email 
Dear NSGC Member, 
  
My name is Rachel Gore and I am a third-year student in the Johns Hopkins/NHGRI 
Genetic Counseling Training Program. I would like to invite you to participate in a 
research study as part of my master's thesis exploring challenges to obtaining informed 
consent for exome sequencing.  The aim of this study is to better understand how 
genetic counselors approach the informed consent process and how they perceive 
challenges in this area.  These questions are relevant to all genetic counselors, as they 
address the fundamental goal of improving consent practice for patients, research 




• All practicing genetic counselors in any clinical specialty, laboratory or research 
setting are welcome to participate - experience with exome sequencing 
is not required! 
• The online survey will take 15-20 minutes. 
• You will not be asked to provide any personally identifying information. 
• Participation in this study is entirely voluntary; you may stop at any time. 
• To thank you for your time, all participants will receive a $10 Amazon gift 
card.  You will have the option to enter contact information following completion 
of the survey.  This information will not be linked to your responses, which are 
anonymous. 
  
Please click here to access the survey:  https://www.surveymonkey.com/r/exomeconsent 
  
If you have any questions about this research project, please feel free to contact me 
at rachel.gore@nih.gov or my advisor, Barbara Biesecker, at barbarab@mail.nih.gov.  
  
Thank you for your time and consideration. 
  
Sincerely, 
Rachel Gore, BA 
ScM Candidate 2018 
JHU/NHGRI GCTP 
  
Barbara B. Biesecker, PhD 






APPENDIX B: Focus Group Consent Form 
 
Challenges to the Informed Consent Process for Whole Exome Sequencing 
Phase I: Focus Groups 
 
What you should know about this study 
• You are being asked to participate in a focus group for research purposes. 
• Please read this consent form carefully and take as much time as you need.  
• You are a volunteer.  You can choose not to take part and you may leave the 
focus group at any time.   
 
Purpose of research project 
We would like to learn more about challenges to the informed consent process for whole 
exome sequencing as experienced by genetic counselors. Results gathered from this focus 
group will guide the design of an online survey that will be sent to a larger group of 
genetic counselors in the next phase of this study.  
 
Why you are being asked to participate 
You are being asked to join this study because you have professional experience with the 
informed consent process for whole exome sequencing in a clinical or research setting. 
 
Procedures 
During the focus group, you will be asked to discuss your experiences obtaining informed 
consent for whole exome sequencing, and aspects of this process that you have found 
challenging.  You will also be asked to provide feedback about a list of potential 
challenges that we will provide.  You will not be asked any questions about your personal 
life, or about specific cases or patients.  Focus groups will be audio recorded, and the 




There are no physical risks to being in this study. There is a risk that this study will cause 
a minor invasion of your privacy, as we will be discussing professional experiences.  
There is also a minor risk for discomfort if your answers disagree with the rest of the 
group, we expect that all participants will be respectful and honest in their responses.  
 
Benefits 
You may be interested in or learn from the experiences shared by other focus group 
participants.  We hope that this focus group will help us to design a more effective survey 
so that we can gather meaningful information about perceived barriers to implementing 
whole exome sequencing in clinical and research settings. 
 
Protecting data confidentiality 
We will not collect any identifying information during the focus group, and the signed 
consent forms will be stored in a locked filing cabinet separately from the data. 
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Who can I contact if I have additional questions? 
Call the student investigator, Rachel Gore, if you have questions.  Any questions that 
cannot be answered by the student investigator will be forwarded to the senior 
investigator. 
           E-mail: rgore2@jhu.edu 
    Telephone: 617-833-3010 
  
 
 What does your signature on this consent form mean? 
 
Your signature on this form means: 
 
• You have been informed about this study’s purpose, procedures, possible benefits 
and risks. 
• You have been given the chance to ask questions before you sign. 
• You have voluntarily agreed to be in this study.  
 
________________________   _____________________________   __________ 
Print name                                  Signature                                                          Date                                                           
                            
________________________   _____________________________   __________ 
























APPENDIX C: Survey Consent Form 
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Challenges to the Informed Consent Process for Whole Exome Sequencing 
Phase II: Online Survey 
Thank you for your interest in this survey! 
We are conducting a research study about genetic counselor’s preceptions about the 
challenges to obtaining informed consent for clinical whole exome sequencing.  You 
are being asked to participate because you are a practicing genetic counselor and a 
member of the National Society of Genetic Counselors. You are eligible to 
participate whether or not you have had direct experience with whole exome 
sequencing. 
Responding to this survey request is voluntary; it is your choice.  Completing this 
survey and submitting it to us means you consent to participate in the study. You 
may choose not to answer any question that we ask. 
This survey will take about 20 minutes, and will ask that you consider the challenges 
to obtaining informed consent for whole exome sequencing in a hypothetical 
scenario.  We will not ask you for any personal or identifiable information, and you 
will not be prompted to share any information about your patients.   
If you choose to complete the survey, you will have the option of providing contact 
information to receive a $10 gift card to tahnk you for your participation.   This 
information will not be linked to your survey responses. 
This project is being conducted by the National Human Genome Research Institute 
(NHGRI) as part of a masters thesis project.  If you have any questions about the 














APPENDIX D: BWS Attribute List 
1. Explaining the technological complexities of sequencing: Defining genetics/genomics 
concepts (e.g. genes, exons and mutations), and the process used to sequence all known 
coding regions of the genome in a single test.  
 
2. Deliberating about secondary findings and their implications: describing the 
possibility that sequencing could identify a mutation in a gene that is unrelated to the primary 
indication for testing, but is associated with increased risk for a preventable or treatable 
disease.   
 
3. Explaining the evolution of variant interpretation: classification of sequencing results 
may vary based on laboratory practices and may also change over time as more data is 
collected. 
 
4. Assessing patient understanding of key content: using verbal and non-verbal cues to 
determine whether the patient has understood the risks, benefits and limitations of whole 
exome sequencing so that they can make an informed decision about testing.    
 
5. Managing patient expectations about the results: communicating the inability to predict 
whether the test will yield results that impact diagnosis, treatment or daily life.  
 
6. Explaining the meaning of a negative result: testing may not identify any variants, but 
this does not rule out the possibility that there is an underlying genetic cause that could not be 
detected by sequencing.  
 
7. Conveying potential implications for relatives: if testing identifies a genetic cause for 
the patient’s symptoms or a secondary finding, it is possible that other family members are at 
risk for the same condition and may need help communicating this information or pursuing 
follow-up testing.  
 
8. Warning for insurance discrimination: though the Genetic Information 
Nondiscrimination Act (GINA) prevents health insurance companies from requesting or 
altering coverage based on genetic information, GINA does not protect against the risk of 
discrimination by companies selling life, disability or long-term insurance. 
 
9. Tailoring consent based on indication and context: the parents in this scenario may 
have different consent needs due to their previous experience with genetic testing, than 
patients in a research setting or other specialty. 
 
10. Engaging patients in collaborative decision-making: encouraging a dialogue in which 
patients discuss the risks and benefits they are considering when making a decision about 
whether or not to consent to undergoing sequencing.  
 
11. Explaining variants of uncertain significance: it is possible that sequencing will 
identify a genetic change, but there will not be enough information available to determine 
whether or not this variant is the underlying cause of the patient’s symptoms.   
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APPENDIX E: Survey 
 
Challenges to the Informed Consent Process for Whole Exome Sequencing 
Phase II: Online Survey 
 
Student Investigator: Rachel Gore  
             NHGRI/JHU Genetic Counseling Training Program 
Senior Investigator:  Barbara Biesecker, PhD 
            NHGRI Social and Behavioral Research Branch 
 
 
Please complete the following questions about yourself and your experience as a 
genetic counselor: 
 
How old are you?    (fill in)  
 
What is your gender? 
 
Male              Female   Prefer to self-describe: (fill in) 
 
With which racial or ethnic group do you most identify? 
 
Caucasian       African American           Hispanic        Asian        Other 
 
For how many years have you been a practicing genetic counselor? 
  
< 5                      5-9          10-19     20-29             30 + 
 
What geographic region of the United States do you practice in? 
 
Northeast  Midwest  South       West         Other 
 
Which best reflects the greatest percentage of your current work responsibilities? 
 
Clinical Care    Research   Laboratory   Other 
 
How would you best describe your current specialty? 
 
Pediatrics  Prenatal   Cancer   Other 
 
How many times have you obtained informed consent for whole exome sequencing? (For 
either clinical or research purposes) 
 




For the next section, mark your level of agreement with the following statements: 
 
“It really disturbs me when I am not able to follow another person’s train of thought” 
 
1 2 3 4 5 
Not at all 
characteristic of me 
   Entirely 
characteristic of me 
 
“If I am uncertain about the responsibilities involved in a particular task, I get very 
anxious” 
 
1 2 3 4 5 
Not at all 
characteristic of me 
   Entirely 
characteristic of me 
 
“Before any important task, I must know how long it will take” 
 
1 2 3 4 5 
Not at all 
characteristic of me 
   Entirely 
characteristic of me 
  
“I don’t like to work on a problem unless there is a possibility of getting a clear-cut and 
unambiguous answer”  
 
1 2 3 4 5 
Not at all 
characteristic of me 
   Entirely 
characteristic of me 
 
“The best part of working on a jigsaw puzzle is putting in that last piece” 
 
1 2 3 4 5 
Not at all 
characteristic of me 
   Entirely 
characteristic of me 
 
“I am often uncomfortable with people unless I feel that I can understand their behavior” 
 
1 2 3 4 5 
Not at all 
characteristic of me 
   Entirely 
characteristic of me 
 
“A good task is one in which what is to be done and how it is to be done are always 
clear” 
 
1 2 3 4 5 
Not at all 
characteristic of me 
   Entirely 
characteristic of me 
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Whole exome sequencing can find variants in many genes at once.  
 
True       False 
 
Whole exome sequencing will find variants that cannot be interpreted at the present time.  
 
True       False 
 
Whole exome sequencing could find that a person has a high risk for a disorder even if 
they do not have symptoms.  
 
True       False 
 
Whole exome sequencing may not find the cause of a disorder even if it is genetic.  
 
True       False 
 
The gene variants that whole exome sequencing can find today could have different 
meanings in the future as scientists learn more about how genes work.  
 
True       False 
 
Whole exome sequencing will not find any variants in people who are healthy. 
 


















For the remainder of the survey questions, consider your response to the following 
scenario: 
 
Samuel is a seven-year-old male with a history of global developmental delay that first 
presented at age eighteen months with delays in growth, walking, and speech.  He passed 
his newborn hearing and vision screenings, and has had a normal brain MRI.  He 
received early intervention services and is currently in school in a special education 
program. He has previously been evaluated in the general genetics clinic and has had 
karyotype and microarray analyses as well as Fragile X testing that were all normal.  He 
was offered a follow-up appointment at the clinic for further diagnostic testing through 
whole exome sequencing that has recently become available.  He will be accompanied by 
his parents.  This is your first time meeting the family, and you have an hour scheduled to 
complete the informed consent process.  
 
 
“I am confident in my ability to communicate the benefits and limitations of whole 
exome sequencing to this family” 
 
1       2         3            4     5          6              7 
Strongly Disagree       Strongly Agree 
 
 
“I know what to say to explain the types of potential results they could receive” 
 
1       2         3           4     5          6              7 
Strongly Disagree       Strongly Agree 
 
 
“Samuel’s parents will be able to manage the scope of information in the informed 
consent process” 
 
 1       2         3            4     5          6              7 
Strongly Disagree       Strongly Agree 
 
 
“Samuel’s parents have the ability to make an informed decision about whole exome 
sequencing” 
 
1       2         3            4     5          6              7 








For the next sections of the survey you will be presented with a series of counseling 
elements that are part of the process of obtaining informed consent for whole exome 
sequencing. Please review all of the elements before beginning this section of the survey; 
you will be able to access the explanations of each item again at any point during the 
survey: 
 
Rate the degree to which you feel that each of these is challenging to do well: 
 (Sliding scale from 0 to 100) 
 
1. Describing the technological complexities of sequencing  
 
2. Deliberating about the implications of secondary findings  
 
3. Explaining the evolution of variant interpretation 
 
4. Assessing patient understanding of key content  
 
5. Managing patient expectations about the results  
 
6. Clarifying the meaning of a negative result  
 
7. Conveying potential implications for relatives  
 
8. Warning for insurance discrimination 
 
9. Tailoring consent based on indication and context 
 
10. Engaging patients in collaborative decision-making  
 






















You will now be presented with a series of choice sets containing five of these counseling 
elements. For each set of counseling elements, please select the one that you think is 
most important and the one that is least important to obtaining meaningful informed 
consent from Samuel’s parents.  You will be asked this question repeatedly with different 
counseling elements. You may review explanations of each element at the bottom of the 
page. 
(Sample choice sets, eleven were presented in total) 
Most 
Important 
Counseling Elements of Informed 




























Counseling Elements of Informed 


























Please take some time to answer the following questions in your own words: 
 
Are Samuel and his parents comparable to patients that you would expect to see in your 
practice? 
           Yes            No 
How so? 
 
What concerns do you have about approaching the informed consent process for whole 
exome sequencing with Samuel and his parents? 
 
What concerns do you expect Samuel’s parents to have about whole exome sequencing? 
 
 
Describe your experience completing the most-least challenging exercise.  Did you feel it 
was challenging to select one option? If so, what was most difficult? 
 
 
Please provide any additional comments about your experience taking this survey: 
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